Comparability analysis of anti-CD20 commercial (rituximab) and RNAi-mediated fucosylated antibodies by two LC-MS approaches
Author:
Publisher
Informa UK Limited
Subject
Immunology,Immunology and Allergy
Link
http://www.tandfonline.com/doi/pdf/10.4161/mabs.24814
Reference34 articles.
1. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma
2. Rituximab for Rheumatoid Arthritis
3. Rituximab in the treatment of rheumatoid arthritis
4. Mechanism of Cytotoxicity Induced by Chimeric Mouse Human Monoclonal Antibody IDEC-C2B8 in CD20-Expressing Lymphoma Cell Lines
5. Rituximab (Anti-CD20) Therapy of B-Cell Lymphomas: Direct Complement Killing is Superior to Cellular Effector Mechanisms
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Recent advancements in disulfide bridge characterization: Insights from mass spectrometry;Rapid Communications in Mass Spectrometry;2024-02-16
2. Elucidating chemical and disulfide heterogeneities in rituximab using reduced and non‐reduced peptide mapping;Journal of Separation Science;2022-06-14
3. Coupling CRISPR interference with FACS enrichment: New approach in glycoengineering of CHO cell lines for therapeutic glycoprotein production;Biotechnology Journal;2022-05-25
4. Analytical Similarity Assessment of Biosimilars: Global Regulatory Landscape, Recent Studies and Major Advancements in Orthogonal Platforms;Frontiers in Bioengineering and Biotechnology;2022-02-09
5. Need for a risk-based control strategy for managing glycosylation profile for biosimilar products;Expert Opinion on Biological Therapy;2021-09-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3